NCT07147946

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Evaluation of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 666 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	TQC3721 Suspension for inhalation	TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor
DRUG	Placebo of TQC3721 Suspension for Inhalation	Placebo without drug substance

Timeline

• Start date: 2025-09-01
• Primary completion: 2027-03-01
• Completion: 2027-06-01
• First posted: 2025-08-29
• Last updated: 2025-09-10

Locations

76 sites across 1 country: China